Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?

Key Takeaways BMY's 2025 revenues were flat as 17% growth in new drugs offset a 15% drop in legacy brands.BMY expects legacy sales to fall 12-16% in 2026, guiding revenues to $46.0-$47.5B.BMY faces rising oncology and cardiovascular competition, including MRK's Keytruda and CYTK's Myqorzo.Bristol Myers Squibb’s (BMY) performance in the recently reported fourth-quarter and full-year 2025 reflects an ongoing transition in its revenue base, with growth from newer products partially offsetting continued decline ...